Open Access
Review
Table 1
- Current regimen of treatment for lung cancer.
Drug name | Generic name | Use | ||
Xeloda | Capecitabine | anti-metabolites | ||
Avastin | Bevacizumab | VEGF/VEGFR inhibitors | ||
Tarceva | Erlotinib | EGFR inhibitors | ||
Cytoxan | Cyclophosphamide | alkylating agents | ||
Taxol | Paclitaxel | mitotic inhibitorsa | ||
Taxotere | Docetaxel | mitotic inhibitors | ||
Gemzar | Gemcitabine | antimetabolites | ||
Erbitux | Cetuximab | EGFR inhibitors | ||
Alimta | Pemetrexed | antimetabolites | ||
Navelbine | Vinorelbine | mitotic inhibitors | ||
Platinol | Cisplatin | alkylating agents | ||
Trexall | Methotrexate | antimetabolites, antipsoriatics, antirheumatics | ||
Ethyol | Amifostine | antineoplastic detoxifying agents | ||
Iressa | Gefitinib | EGFR inhibitor | ||
Neosar | Cyclophosphamide | alkylating agents | ||
Platinol-AQ | Cisplatin | alkylating agents | ||
Photofrin | Porfimer | miscellaneous antineoplastics | ||
Onxol | Paclitaxel | mitotic inhibitors |